High-Content Screening for AI-based Drug Discovery
Our platform benefits from new technologies that have been widely developed in recent years (AI, cellular imaging, robotization). The convergence of these technologies and the close collaboration of data scientists and biologists make it possible to create biological models of very large size and significance.
The predictive ability of Artificial Intelligence AI combined with the descriptive and explanatory capacity of Molecular Modeling MM, enriched with quantitative and functional High-Content Screening HCS is the platform of SYNSIGHT and what make us different.
Solve complex systems like Protein-Protein Interactions with our convergence
of High-Content Screening and Artificial Intelligence
Accelerate and unrisk your R&D
Understand the mode of action of your drug candidate in biological systems with the aid of Molecular Modeling
To learn more about partnering opportunities, please contact us email@example.com
SYNSIGHT a/s SABNP – Batiment Maupertuis Université d’Evry Rue du Père André Jarlan 91000 EVRY FRANCE
SYNSIGHT Genopole Entreprises 4 rue Pierre Fontaine 91058 EVRY
Phone Number: (+33) 01 69 47 01 76